Navigation Links
Metabolic Solutions Development Company Launches Phase 2a Trial of Its Second Compound to Treat Type 2 Diabetes
Date:3/29/2011

KALAMAZOO, Mich., March 29, 2011 /PRNewswire/ -- Metabolic Solutions Development Company (MSDC), a drug discovery and development company exploiting novel molecular targets to treat metabolic diseases, announced today that it has launched a Phase 2a trial for MSDC-0602, the company's second drug candidate for the treatment of type 2 diabetes.  The 28-day, randomized, double-blind, comparator- and placebo-controlled clinical trial will involve approximately 125 patients at 15 planned sites throughout the United States.

MSDC-0602 is a selective modulator of mitochondrial metabolism that modifies nutrient-sensing pathways leading to improved insulin action without direct activation of nuclear transcription factors.  "Because this novel mechanism of action does not depend on direct activation of nuclear transcription factors, type 2 diabetic patients treated with MSDC-0602 are not expected to experience fluid retention or weight gain as do patients treated with the currently marketed PPARy agonists," said Dr. Jerry Colca, president and chief scientific officer of MSDC.  

In addition to gathering additional safety and tolerability data, the Phase 2a trial will evaluate the reduction in fasting plasma glucose following once-daily dosing for 28 consecutive days in patients with type 2 diabetes.  Patients taking MSDC-0602 will be compared to those taking 45 mg of pioglitazone and placebo. This study follows the completion of two Phase 1 trials.  No safety concerns were observed in those studies. Following this Phase 2a trial, additional safety and expanded efficacy data will be gathered in a Phase 2b study of MSDC-0602 that is targeted to begin in the first quarter of 2012.

In October 2010, MSDC announced that it had raised $23.5 million to conduct the Phase 2a trial of MSDC-0602 and complete the Phase 2b study of MSDC-0160, the company's pioneer compound for the treatment of metabolic diseases associated with altered mi
'/>"/>

SOURCE Metabolic Solutions Development Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dave Anderson and William Thomsen Join SRI Internationals Center for Advanced Drug Research to Lead Programs in Proteomics and Metabolic Disease Drug Discovery
2. Bionovo Announces Publication Describing How Metabolic Adaptability Contributes to the Metastasis of Tumors
3. Metabolic Status Before Pregnancy Predicts Subsequent Gestational Diabetes
4. Metabolic Solutions Development Company to Present Research Findings to European Association for the Study of Diabetes
5. Windhover Information Names D-Tagatose One of Top 10 Most Promising CV/Metabolic Drugs in Development
6. Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity From Its Broad Metabolic Disease Franchise at ADA Scientific Sessions
7. Reportlinker Adds Stakeholder Opinions: Cardiovascular and Metabolic Generics - Generics continue to gain prominence
8. Isis Pharmaceuticals to Discuss Its Metabolic Franchise in a Conference Call on Wednesday, April 28
9. Reportlinker Adds Metabolic Endocrinology Hypocalcemia
10. Metabolic Solutions Development Company To Test Potential Treatment for Alzheimers
11. Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease; Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver Disease and Metabolic Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014  Tasly Pharmaceuticals, Inc., ... modernize medicine, announced today the launch of Deepure. ... developed to address men and women concerned with ... vibrant into old age while helping keep their ... condition-specific, whole-food and herb-based formulas, namely, ProHeart PLUS, ...
(Date:9/30/2014)... 2014  Decision Resources Group finds that the markets ... , Russia , ... (BRIC) will see robust expansion as these economies expand ... procedures. Although revenues will be somewhat impeded by poor ... approval times and demand for low-cost products, the market ...
(Date:9/30/2014)... 2014   Easy Breathe , the fastest growing ... that it now offers the revolutionary AirSense ... first sleep apnea therapy devices with internal cellular modems.  ... track and share real-time data on each user,s quality ... therapy.  In addition, the internal modem allows the CPAP ...
Breaking Medicine Technology:Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4
... American Oriental Bioengineering, Inc. (NYSE: AOB ... dedicated to improving healthcare through the development, manufacture ... and over-the-counter ("OTC") products, today announced that its ... and Chief Financial Officer, Ms. Lily Li were ...
... Jan. 25, 2011 Reportlinker.com announces that ... in its catalogue: Brand ... small molecule brand erosion post-patent expiry ... IntroductionPharma is facing slowing sales growth ...
Cached Medicine Technology:American Oriental Bioengineering's CEO and CFO Visit the United States as Entrepreneur Representatives of President Hu Jintao's Delegation 2Reportlinker Adds Brand Erosion Post-Patent Expiry - An analysis of small molecule brand erosion post-patent expiry 2
(Date:10/1/2014)... 01, 2014 Insuranceragents.info has released ... good life insurance plan for vulnerable family members. , ... family members. Providers in the family should always carry ... financial hardships for the rest of the family. ... Families can benefit more from temporary coverage or from ...
(Date:10/1/2014)... Hillsboro, Oregon (PRWEB) October 01, 2014 ... curing solutions , continues to expand the business worldwide. ... engineering along with additional capacity for manufacturing efforts. The ... over the last five years and expects this growth ... UV LED curing technology gains worldwide adoption. , ...
(Date:10/1/2014)... N.C. A new genetic finding from Duke Medicine ... anxiety and depression might also be hard-wired to gain ... and heart disease. , An estimated 13 percent of ... genetic susceptibility, and knowing this could help them reduce ... diet, exercise and stress management. , "Genetic susceptibility, psychosocial ...
(Date:10/1/2014)... 2014 Diet Doc understands that many of ... weight and their dieting attempts could be easily sabotaged by ... hormone diet treatments into their programs as a way ... fast and effective weight loss results, it also allows patients ... to maintain their weight for the future. , Earlier versions ...
(Date:10/1/2014)... On Sept. 9, Chapín Coffee was ... Martha Stewart American Made Awards (MSAMAs), an annual competition ... in the fields of crafts, design, food and style. ... finalist in the MSAMAs, which celebrates entrepreneurs and artisans ... local communities and changing the way we shop, work ...
Breaking Medicine News(10 mins):Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4Health News:Chicago Coffee Start-up Makes a Big Impact, Earns National Recognition 2
... findings reported at symposium on gastrointestinal cancers , , THURSDAY, ... zeroed in on a biomarker that could detect colorectal ... invasive and more accurate way than existing blood tests. ... also differentiate between early- and late-stage disease, the researchers ...
... ZYTO Corp. (Pink Sheets:,ZYTC) has announced the appointment of ... Howard as C.F.O., The internal appointments come as ... Dr. Vaughn R. Cook, company founder, president and,C.E.O. Howard ... the,financial responsibilities., Howard joined ZYTO in April of ...
... is a,statement by Blue Shield of California CEO Bruce Bodaken ... universal coverage, I,m disappointed that we,did not clear this hurdle ... make perfection the enemy of the good. This bill should ... We have waited too long to make health coverage for ...
... Jan. 23 InterMune, Inc.,(Nasdaq: ITMN ) today ... InterMune, will present at the 2008 Wachovia Healthcare,Conference in ... To access a live audio webcast of the ... the investor relations page of InterMune,s,corporate website at ...
... RARITAN, N.J., Jan. 23 Johnson & Johnson,Pharmaceutical ... a New Drug Application (NDA) to the U.S. ... release (IR),tablets, an investigational oral analgesic for the ... to the American Pain Foundation, more than 25 ...
... treatments to blame, study finds , , WEDNESDAY, Jan. 23 ... to treat people with peripheral arterial disease (PAD) than ... finds. , Both PAD (blocked abdomen and leg arteries) ... same methods, including medication, surgery and endovascular techniques such ...
Cached Medicine News:Health News:New Colon Cancer Test Might Spot Trouble Earlier 2Health News:New Colon Cancer Test Might Spot Trouble Earlier 3Health News:ZYTO Corp. Appoints New Chief Operations Officer and New Chief Financial Officer 2Health News:InterMune to Present at the 2008 Wachovia Healthcare Conference 2Health News:New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets 2Health News:New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets 3Health News:New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets 4Health News:Peripheral Arterial Disease Costlier to Treat Than Heart Trouble 2
Inquire...
Microseal 'F' foil, seals plates for cold storage (or cycling >25l), disposable, pkg of 100...
Sterilization: sterilized Yes...
Effective adhesive, may be removed from plate without residue. Transparent film for easy visual monitoring of samples...
Medicine Products: